Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...
Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
Dr. Thomas Wagner, founder of the biotech company Orbis Health Solutions and cancer researcher, has made it his life's mission to find a way to treat cancer without the dreaded side effects that ...
The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...
However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.
Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt ... rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks ...
News Medical on MSN9d
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMRChronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback